Heart failure & cardiomyopathiesCohort study
Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy
- Retrospective cohort study
- multimodality imaging
Authors' conclusion
Our study indicates a poor correlation between reduction in 99mTc-DPD uptake at follow-up and numerous established biomarkers of ATTR-CM treatment response.
Study context
- Population
- ATTR-CM patients at the UK National Amyloidosis Centre receiving amyloid-specific disease-modifying therapy (DMT) with pre- and post-treatment 99mTc-DPD SPECT-CT scans
- Participants
- 66 patients
- Outcome
- Change in myocardial percentage injected dose (PID) on 99mTc-DPD scintigraphy vs change in validated biomarkers of disease severity
Main finding
As reported in the abstract
Change in myocardial PID on 99mTc-DPD scintigraphy · median 27.5 months (Q1-Q3: 21.9-33.1 months) between scans
Mean reduction from pre-DMT myocardial percentage injected dose (PID)
1.5 ± 1.5%
Discordance: improvement on follow-up 99mTc-DPD despite disease progression
28/66 patients (42.4%)
Observational data: associations, not effects.
Original publication
Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy. JACC Cardiovasc Imaging. Published 9 July 2025. doi:10.1016/j.jcmg.2025.03.014
Summarised from the published abstract; every number is checked against it